CN110548211B - Medicine balloon catheter with plugging function - Google Patents
Medicine balloon catheter with plugging function Download PDFInfo
- Publication number
- CN110548211B CN110548211B CN201910964307.6A CN201910964307A CN110548211B CN 110548211 B CN110548211 B CN 110548211B CN 201910964307 A CN201910964307 A CN 201910964307A CN 110548211 B CN110548211 B CN 110548211B
- Authority
- CN
- China
- Prior art keywords
- balloon
- tube
- drug
- medicine
- sacculus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 185
- 229940079593 drug Drugs 0.000 title claims description 102
- 230000010412 perfusion Effects 0.000 claims abstract description 22
- 238000000576 coating method Methods 0.000 claims description 33
- 239000011248 coating agent Substances 0.000 claims description 31
- 210000005077 saccule Anatomy 0.000 claims description 28
- 238000011049 filling Methods 0.000 claims description 20
- 230000001681 protective effect Effects 0.000 claims description 15
- 238000003466 welding Methods 0.000 claims description 13
- 230000006837 decompression Effects 0.000 claims description 11
- 238000001802 infusion Methods 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 239000013013 elastic material Substances 0.000 claims description 3
- 238000012800 visualization Methods 0.000 claims 6
- 230000012782 tube fusion Effects 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 description 20
- 238000000034 method Methods 0.000 description 14
- 238000011161 development Methods 0.000 description 8
- 238000004026 adhesive bonding Methods 0.000 description 6
- -1 taxanes Chemical class 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical class C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229960005167 everolimus Drugs 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003618 dip coating Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229960001302 ridaforolimus Drugs 0.000 description 2
- 238000009991 scouring Methods 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000002966 stenotic effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960001967 tacrolimus Drugs 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229960001025 iohexol Drugs 0.000 description 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
- 229960002603 iopromide Drugs 0.000 description 1
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000009740 moulding (composite fabrication) Methods 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1011—Multiple balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1027—Making of balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1011—Multiple balloon catheters
- A61M2025/1013—Multiple balloon catheters with concentrically mounted balloons, e.g. being independently inflatable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1079—Balloon catheters with special features or adapted for special applications having radio-opaque markers in the region of the balloon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1095—Balloon catheters with special features or adapted for special applications with perfusion means for enabling blood circulation while the balloon is in an inflated state or in a deflated state, e.g. permanent by-pass within catheter shaft
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1097—Balloon catheters with special features or adapted for special applications with perfusion means for enabling blood circulation only while the balloon is in an inflated state, e.g. temporary by-pass within balloon
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
The application provides a take medicine sacculus pipe of shutoff function, medicine sacculus pipe include outer tube, intervalve, perfusion tube and inner tube from skin to inlayer in proper order, the distal end of inner tube and perfusion tube follow the distal end of intervalve stretch out, medicine sacculus pipe still include medicine sacculus subassembly, be located near-end sacculus and the distal end sacculus of the near-end and the distal end of medicine sacculus subassembly respectively, the distal end and the near-end of near-end sacculus connect on the outer wall of outer tube, the near-end of distal end sacculus connect the distal end of intervalve, the distal end of distal end sacculus connect on the outer wall of perfusion tube, intervalve and perfusion tube between the clearance with the inner chamber of distal end sacculus be linked together, medicine sacculus subassembly near-end and distal end connect on the outer wall of outer tube, medicine sacculus subassembly is located between distal end sacculus and the near-end sacculus, the proximal end of the perfusion tube is connected to the outer wall of the inner tube.
Description
Technical Field
The application relates to a medicine balloon catheter with a plugging function.
Background
In recent years, with the rapid development of neurosmagraphy, catheter technology and materials, computers and other sciences, intravascular interventional techniques are becoming mature in the aspect of treating vascular diseases, and are determined by doctors and patients on the basis of the characteristics of minimal invasion, safety, effectiveness and the like, so that the intravascular interventional techniques are one of the important methods for treating vascular diseases at present.
In the interventional therapy mode, a balloon catheter is needed, the balloon catheter is a tool for intravascular angioplasty, the balloon is sent to an atherosclerotic and stenotic part through a guide wire and a guide catheter, the balloon is expanded by pressure, plaques are cracked, blood vessels are expanded, and blood flow is improved, so that the method is a novel effective technology for treating cardiovascular diseases in recent years. However, 30-40% of patients after angioplasty have restenosis due to vascular endothelial injury, smooth muscle cell hyperproliferation, and lack of support by dilated vessels. On the basis, the technology of the intravascular stent treatment is developed. This technique is to install a metal mesh stent on the outside of a balloon, deliver the stent tube to the lesion site through a balloon catheter, and permanently insert the stent into the intima of the coronary artery of a patient after the balloon is expanded, but there is still about 10-20% of patients' blood vessels that undergo stent restenosis after stent expansion due to smooth muscle proliferation caused by immune reaction of the human body. Since the stent is permanently embedded in the intima of the coronary artery of the patient, it is not possible to remove the implanted stent and perform a second stent implantation. In order to solve the problem of blood vessel stenosis caused by stent implantation, a drug-loaded stent is rapidly a main means of cardiovascular stent implantation treatment technology in recent years. Because the surface of the metal stent is coated with a layer of medicine for inhibiting the growth of smooth muscle, the restenosis rate of a patient after operation can be reduced to below 5 percent. However, compared to the conventional bare stent without drug loading, the drug-loaded stent is very expensive and some patients may develop thrombus to cause serious adverse reactions due to the influence of the polymer material on the drug-loaded coating.
To solve the above problems, balloon catheters with drug coatings have been developed. The balloon catheter is characterized in that a medicine with a therapeutic effect is coated on the outer surface of a balloon, namely a medicine coating is formed on the outer wall of the balloon. When the saccule reaches the pathological change part in the blood vessel, the saccule expands to make the medicine coating on the surface contact with the inner wall of the blood vessel. The medicine is released and acts on the pathological change part, thereby achieving the purpose of treating and preventing the restenosis in the blood vessel. Even if the blood vessel of the patient is narrowed and blocked, the drug-carrying balloon catheter can be used for secondary treatment again.
Although drug-coated balloon catheters have a positive therapeutic effect, users find in practice: in the process that the saccule with the medicine sprayed on the surface enters the blood vessel, the medicine on the surface of the saccule can fall off due to friction with the inner wall of the blood vessel, so that the medicine cannot be completely delivered to a diseased part by the medicine saccule. How to coat the medicine on the outer surface of the balloon as much as possible and how to keep the medicine from being washed and lost by blood in a blood vessel in the process of conveying the balloon to a lesion part through a catheter become the technical problem, and no better solution is provided at present.
The basic principle of the drug-coated balloon dilatation catheter is local drug delivery, and the drug coating is important as an important technical index of the drug-coated balloon. The firmness of the drug coating in the blood vessel, the drug release capacity in the artery, and the drug absorption capacity by the blood vessel are all determined by the drug coating. At present, a plurality of types of medicine balloons on the market at home and abroad adopt medicines and dispersing agents to be coated on the balloons together, and the firmness of the medicine coating is controlled by the dispersing agents. However, such a drug coating may introduce one or more substances other than the effective drug, and there is a certain probability that a safety problem such as allergy or adverse stimulus reaction may occur in the human body.
The basic principle of the drug-coated balloon dilatation catheter is local drug delivery, and the drug coating is important as an important technical index of the drug-coated balloon. The firmness of the drug coating in the blood vessel, the drug release capacity in the artery, and the drug absorption capacity by the blood vessel are all determined by the drug coating. At present, a plurality of types of medicine balloons on the market at home and abroad adopt medicines and dispersing agents to be coated on the balloons together, and the firmness of the medicine coating is controlled by the dispersing agents. However, such a drug coating may introduce one or more substances other than the effective drug, and there is a certain probability that a safety problem such as allergy or adverse stimulus reaction may occur in the human body.
When the drug coating is released quickly, more drugs can be washed away by blood in the conveying process, and the drugs acting on local parts are very few. The drug absorption amount can be locally increased by increasing the drug loading amount of the balloon coating, but a large amount of redundant drug flows to the far end of the blood vessel, so that the health of a patient is influenced.
Because the expansion time of ordinary medicine sacculus expansion pipe is short, the medicine is not well released, and the blood vessel is taken out of at ordinary sacculus, owing to lose support can quick rebound to the original state, so the problem and the difficult point that ordinary medicine sacculus expansion pipe faced at present have:
1. when the drug coating is released quickly, more drugs can be flushed away by blood in the conveying process;
2. the drug-loaded balloon is attached to the vessel wall in a short time, the supporting time is short, and the physical resilience of the vessel is fast;
3. the drug adheres to the wall in a short time and is difficult to be absorbed by the vessel wall in a large amount, so that a better treatment effect cannot be achieved;
4. the drug coating is easy to fall off to generate particles and thrombus.
Disclosure of Invention
The technical problem that this application will be solved provides a medicine sacculus pipe of area shutoff function.
In order to solve the technical problem, the application provides a medicine balloon catheter with a plugging function, which sequentially comprises an outer tube, an intermediate tube, a perfusion tube and an inner tube from the outer layer to the inner layer, wherein the far ends of the inner tube and the perfusion tube extend out of the far end of the intermediate tube, the medicine balloon catheter further comprises a medicine balloon assembly, a near-end balloon and a far-end balloon which are respectively positioned at the near end and the far end of the medicine balloon assembly, the far end and the near end of the near-end balloon are connected onto the outer wall of the outer tube, the near end of the far-end balloon is connected at the far end of the intermediate tube, the far end of the far-end balloon is connected onto the outer wall of the perfusion tube, a gap between the intermediate tube and the perfusion tube is communicated with the inner cavity of the far-end balloon, the near end and the far end of the medicine balloon assembly are connected onto the outer wall of the outer tube, the drug balloon component is positioned between the far-end balloon and the near-end balloon, the near end of the perfusion tube is connected to the outer wall of the inner tube, the near end of the inner tube penetrates through the intermediate tube and the outer tube to form an RX port communicated with the outside, the outer tube and the intermediate tube are provided with a near-end balloon pressure charging and releasing port, the near-end balloon pressure charging and releasing port is positioned in the inner cavity of the near-end balloon, a gap between the intermediate tube and the perfusion tube is communicated with the inner cavity of the near-end balloon through the near-end balloon pressure charging and releasing port, the outer tube is provided with one or more drug balloon pressure charging and releasing ports, the drug balloon pressure charging and releasing port is positioned in the inner cavity of the drug balloon component, and the gap between the outer tube and the intermediate tube is communicated with the inner cavity of the drug balloon component through the drug balloon pressure charging and releasing port, one or more self-filling ports are formed in the outer tube, the middle tube and the filling tube, the self-filling ports are located on one side of the near end of the near-end balloon, and gaps between the inner tube and the filling tube are communicated with the outside through the self-filling ports.
Preferably, the medicine balloon component comprises a medicine balloon and a protection balloon coated outside the medicine balloon, the outer wall of the medicine balloon is coated with a medicine coating, the protection balloon is axially provided with 2 or more than 2 splitting lines, and after the medicine balloon is expanded, the protection balloon is squeezed by the medicine balloon and then splits along the splitting lines.
Preferably, the protective balloon is made of an elastic material, and when the protective balloon is pressed by the medicine balloon and is split along the splitting line, the protective balloon is curled to form 2 or more extrusion lines to be attached to the outer surface of the medicine balloon.
Preferably, the proximal end of the middle tube is connected with a distal-proximal balloon pressure-relief catheter seat, the injection port of the distal-proximal balloon pressure-relief catheter seat is communicated with the inner cavity of the middle tube, the proximal end of the outer tube is connected with a drug balloon pressure-relief catheter seat, and the injection port of the drug balloon pressure-relief catheter seat is communicated with the gap between the outer tube and the middle tube.
Preferably, the inner tube in be provided with first development ring, two second development rings, third development ring, first development ring be located the inner chamber of distal end sacculus, the second development ring be located the inner chamber of medicine sacculus subassembly, the third development ring be located the inner chamber of proximal end sacculus.
Preferably, the distal end of the inner tube is further provided with a tip.
Preferably, the outer tube and the intermediate tube are connected at the RX port by welding or bonding.
Preferably, the outer pipe, the middle pipe and the filling pipe are connected at the self-filling opening through welding or bonding.
The utility model provides a take medicine sacculus pipe of shutoff function has following beneficial effect:
(1) after the drug balloon is coated with the drug coating, the outer layer is provided with the protective balloon, and the drug coating is not contacted with blood and vessel walls in the conveying process, so that no drug is lost; the outer protection sacculus is equipped with the split line, and during the expansion of medicine sacculus, the outer protection sacculus is separated by the split line after receiving the extrusion, and medicine sacculus coating exposes and contacts with the vascular wall, release medicine.
(2) The pipe design has from the notes mouth of irritating, and in the medicine sacculus expansion release medicine process, blood does not influence the blood flow from the notes mouth flow to the distal end, can increase medicine sacculus adherence time, and the support time is longer, and more medicines are absorbed by the vascular wall.
(3) The catheter is provided with a plugging balloon, in the process of expanding the medicine balloon, the plugging balloon plugs the far end and the near end of the medicine balloon, so that the flow direction of dropped coating particles to the far end is reduced, and the scouring of blood flow to the medicine coating is avoided when the medicine balloon expands to transfer medicines.
(4) The drug coating is composed of an excipient and an anti-proliferation drug, and the drug absorption amount is sufficient, the drug can be continuously effective, and sufficient remodeling time is provided for blood vessels.
Drawings
Fig. 1 is a schematic structural diagram of a drug balloon catheter with an occlusion function according to the present application;
fig. 2 is a partial structural schematic diagram of a drug balloon catheter with an occlusion function according to the present application.
Fig. 3 is a schematic structural diagram of a balloon assembly of a drug balloon catheter with an occlusion function according to the present application.
Wherein: 1. a tip; 2. a first developing ring; 3. a distal balloon; 4. a drug balloon; 5. a drug coating; 6. the medicine saccule is filled with a pressure relief port; 7. a protective balloon; 8. a second developing ring; 9. a proximal balloon; 10. a proximal balloon inflation and deflation port; 11. a third developing ring; 12. a self-priming port; 13. an RX port; 14. the medicine saccule is filled with a pressure relief catheter seat; 15. the far end balloon and the near end balloon are filled with a pressure relief catheter seat; 16. an outer tube; 17. an intermediate pipe; 18. a perfusion tube; 19. an inner tube; 20. the middle pipe is connected with the catheter seat; 21. the outer tube is connected with the catheter seat.
Detailed Description
The present application is further described below in conjunction with the following figures and specific examples to enable those skilled in the art to better understand the present application and to practice it, but the examples are not intended to limit the present application.
As shown in the figures, the drug balloon catheter with the plugging function of the present application comprises an outer tube 16, a middle tube 17, an infusion tube 18 and an inner tube 19 in sequence from an outer layer to an inner layer, the distal ends of the inner tube 19 and the infusion tube 18 extend out from the distal end of the middle tube 17, the drug balloon catheter further comprises a drug balloon assembly, a proximal balloon 9 and a distal balloon 3 respectively located at the proximal end and the distal end of the drug balloon assembly, the distal end and the proximal end of the proximal balloon 9 are connected to the outer wall of the outer tube 16, the proximal end of the distal balloon 3 is connected to the distal end of the middle tube 17, the distal end of the distal balloon 3 is connected to the outer wall of the infusion tube 18, the gap between the middle tube 17 and the infusion tube 18 is communicated with the inner cavity of the distal balloon 3, the proximal end and the distal end of the drug balloon assembly are connected to the outer wall of the outer tube 16, the medicine balloon component is positioned between the far-end balloon 3 and the near-end balloon 9, the near end of the perfusion tube 18 is connected to the outer wall of the inner tube 19, the near end of the inner tube 19 penetrates through the middle tube 17 and the outer tube 16 to form an RX port 13 communicated with the outside, the outer tube 16 and the middle tube 17 are provided with a near-end balloon inflation and decompression port 10, the near-end balloon inflation and decompression port 10 is positioned in the inner cavity of the near-end balloon 9, a gap between the middle tube 17 and the perfusion tube 18 is communicated with the inner cavity of the near-end balloon 9 through the near-end balloon inflation and decompression port 10, the outer tube 16 is provided with one or more medicine balloon inflation and decompression ports 6, the medicine balloon inflation and decompression ports 6 are positioned in the inner cavity of the medicine balloon component, and the gap between the outer tube 16 and the middle tube 17 is communicated with the inner cavity of the medicine balloon component through the medicine balloon decompression port 6, one or more self-filling openings 12 are formed in the outer tube 16, the middle tube 17 and the filling tube 18, the self-filling openings 12 are located on one side of the near end balloon 9, and a gap between the inner tube 19 and the filling tube 18 is communicated with the outside through the self-filling openings 12. The medicine sacculus subassembly include medicine sacculus 4, cladding protection sacculus 7 outside medicine sacculus 4, the outer wall of medicine sacculus 4 coat with medicine coating 5, protection sacculus 7 go up and seted up 2 or more than 2 division lines along the axial, after medicine sacculus 4 expand, protection sacculus 7 receive the extrusion of medicine sacculus 4 after the division line split. The protective balloon 7 is made of elastic material, and when the protective balloon 7 is squeezed by the medicine balloon 4 and split along the splitting line, the protective balloon 7 is curled to form 2 or more squeezing lines to be attached to the outer surface of the medicine balloon 4. The near end of the middle tube 17 is connected with a far and near balloon pressure-relief catheter seat 15, the injection port of the far and near balloon pressure-relief catheter seat 15 is communicated with the inner cavity of the middle tube 17, the near end of the outer tube 16 is connected with a medicine balloon 4 pressure-relief catheter seat, and the injection port of the medicine balloon 4 pressure-relief catheter seat is communicated with the gap between the outer tube 16 and the middle tube 17. Inner tube 19 in be provided with first ring 2, two second ring 8, the third ring 11 that develop, first ring 2 that develop be located distal end sacculus 3's inner chamber in, second ring 8 that develop be located medicine sacculus subassembly's inner chamber, third ring 11 that develop be located the inner chamber of proximal end sacculus 9. The distal end of the inner tube 19 is also provided with a tip 1. The outer tube 16 and the intermediate tube 17 are connected by welding or bonding at the RX port 13. The outer tube 16, the middle tube 17 and the infusion tube 18 are connected with the self-infusion port 12 through welding or bonding.
The preparation method of the drug balloon catheter with the plugging function comprises the following steps:
one end of the outer tube 16 is perforated to form a drug balloon inflation and decompression opening 6; the outer surface of the drug balloon is coated with a drug coating 5 by dip coating or ultrasonic spraying; the surface of the protective saccule 7 is cut to form a splitting line and then is sleeved on the outer layer of the medicine saccule, and then is welded or glued on the outer tube 16, and the medicine saccule pressure charging and releasing port 6 is arranged inside the medicine saccule; the middle tube 17 penetrates into the outer tube 16, the far end of the middle tube 17 is connected with the near end of the far-end saccule 3 through welding or bonding, the near-end saccule 9 is formed into a pressure charging and releasing hole through cutting and welding or gluing, two ends of the near-end saccule 9 are connected with the outer tube 16 through welding or gluing, and the pressure charging and releasing hole of the near-end saccule 9 is arranged in the near-end saccule 9; the middle pipe 17 is internally penetrated with a filling pipe 18, and the self-filling openings 12 are formed by cutting, welding or gluing, and at least one self-filling opening 12 is formed; embedding the mark developing ring into the outer surface of the inner tube 19 through mould pressing to prepare a far-end balloon 3 mark developing ring, a medicine balloon mark developing ring and a near-end balloon 9 mark developing ring; penetrating the inner tube 19 of the developing ring to be marked into the perfusion tube 18, connecting the far end of the far-end saccule 3, the perfusion tube 18 and the inner tube 19 by welding or gluing, and forming the catheter tip 1; cutting and preparing an RX port 13 by welding or gluing; the catheter hub and the outer tube 16 and the catheter hub and the intermediate tube 17 are connected by welding or gluing to form a joint 21 between the outer tube 16 and the catheter hub and a joint 20 between the intermediate tube 17 and the catheter hub.
The application of the medicine balloon catheter with the plugging function comprises the following steps:
after the stenotic blood vessel is pretreated by a balloon, a guide wire passes through the tip end 1 of the catheter and an RX port 13, and the catheter enters the blood vessel through the guide wire; under X-ray, the developing ring is accurately reached to the position of a lesion according to the development of the marking developing rings of the far-end balloon 3, the marking developing rings of the medicine balloon and the marking developing rings of the near-end balloon 9, and the position of the lesion is between the marking developing rings of the medicine balloon; injecting contrast medium or normal saline into the far and near end saccule 9 through the far and near end saccule inflating and decompressing catheter seat 15, and plugging the near end and the far end of the blood vessel at the lesion position after the saccule is inflated; the drug balloon is filled with normal saline or contrast agent for pressurizing through the drug balloon pressure-releasing catheter seat 14, and the drug balloon is expanded and adheres to the wall to release the drug. After the pressure is released, the balloon is decompressed, and the catheter is withdrawn. Due to the design of the self-priming nozzle 12, the time of administration is not limited. After the administration, the vessel is dilated according to the retraction condition of the vessel, and secondary administration is carried out if necessary.
The drug coating 5 comprises excipients and antiproliferative drugs, preferably macrolide immunosuppressants, macrolide antibiotics, rapamycin, structural derivatives and functional analogues of rapamycin, everolimus, structural derivatives and functional analogues of everolimus, paclitaxel, taxanes, temsirolimus compounds, oxazololimus, everolimus, sirolimus, bisolimus, myolimus, deforolimus, tacrolimus or temsirolimus compounds, oxazololimus, everolimus, sirolimus, bisolimus, myolimus, deforolimus, tacrolimus or structures of temsirolimus compounds.
The drug coating 5 is formed by mixing a drug, an excipient and an organic solvent and then coating, wherein the organic solvent is one or more of tetrahydrofuran, methanol, ethanol, isopropanol and acetonitrile; the coating process is one or more of a spraying method, a dip-coating method and a scouring method electrostatic adsorption method.
The excipient is preferably any one or more of iohexol, iopromide or lopamil, polyvinylpyrrolidone (PVP), povidone containing coupled iodine, polyvinyl alcohol (PVA), polyethylene oxide (PEO), polyethylene glycol (PEG), triglycerides, triacetin, capric acid triglycerides, caprylic acid triglycerides, urea, polysorbate, ethylene glycol glucoside, alkyl glycosides, meglumine, pectin, shellac, mannitol, methyl cellulose, vinyl cellulose, hydroxypropyl cellulose, mannitol or acetamide.
The above-described embodiments are merely preferred embodiments for fully illustrating the present application, and the scope of the present application is not limited thereto. The equivalent substitution or change made by the person skilled in the art on the basis of the present application is within the protection scope of the present application. The protection scope of this application is subject to the claims.
Claims (6)
1. A medicine balloon catheter with a plugging function is characterized by comprising an outer tube, a middle tube, a perfusion tube and an inner tube from an outer layer to an inner layer in sequence, wherein the far ends of the inner tube and the perfusion tube extend out of the far end of the middle tube,
the drug balloon catheter also comprises a drug balloon component, a proximal balloon and a distal balloon which are respectively positioned at the proximal end and the distal end of the drug balloon component,
the far end and the near end of the near end saccule are connected on the outer wall of the outer tube,
the near end of the far-end saccule is connected with the far end of the middle tube, the far end of the far-end saccule is connected with the outer wall of the perfusion tube, the gap between the middle tube and the perfusion tube is communicated with the inner cavity of the far-end saccule,
the proximal end and the distal end of the drug balloon component are connected on the outer wall of the outer tube, the drug balloon component is positioned between the distal balloon and the proximal balloon,
the near end of the perfusion tube is connected to the outer wall of the inner tube, the near end of the inner tube passes through the middle tube and the outer tube to form an RX port communicated with the outside,
the outer tube and the middle tube are provided with a near-end balloon pressure charging and releasing port, the near-end balloon pressure charging and releasing port is positioned in the inner cavity of the near-end balloon, the gap between the middle tube and the perfusion tube is communicated with the inner cavity of the near-end balloon through the near-end balloon pressure charging and releasing port,
one or more drug balloon pressure charging and releasing ports are formed in the outer tube, the drug balloon pressure charging and releasing ports are positioned in the inner cavity of the drug balloon component, a gap between the outer tube and the middle tube is communicated with the inner cavity of the drug balloon component through the drug balloon pressure charging and releasing ports,
one or more self-filling ports are arranged on the outer tube, the middle tube and the filling tube, the self-filling ports are positioned on one side of the near end of the near-end balloon, and gaps between the inner tube and the filling tube are communicated with the outside through the self-filling ports;
the drug balloon component comprises a drug balloon and a protective balloon coated outside the drug balloon, the outer wall of the drug balloon is coated with a drug coating, the protective balloon is made of an elastic material, and the protective balloon is axially provided with 2 or more than 2 splitting lines; when the drug balloon is expanded, the protective balloon is pressed by the drug balloon and then splits along the splitting line;
when the protective saccule is squeezed by the medicine saccule to be split along the splitting line, the protective saccule is curled to form 2 or a plurality of squeezing lines to be attached to the outer surface of the medicine saccule.
2. The drug balloon catheter with the plugging function as claimed in claim 1, wherein the proximal end of the middle tube is connected with a distal balloon decompression and inflation catheter seat, the injection port of the distal balloon decompression and inflation catheter seat is communicated with the inner cavity of the middle tube, the proximal end of the outer tube is connected with a drug balloon decompression and inflation catheter seat, and the injection port of the drug balloon decompression and inflation catheter seat is communicated with the gap between the outer tube and the middle tube.
3. The drug balloon catheter with the occlusion function of claim 1, wherein a first visualization ring, two second visualization rings and a third visualization ring are arranged in the inner tube, the first visualization ring is located in the inner cavity of the distal balloon, the second visualization ring is located in the inner cavity of the drug balloon component, and the third visualization ring is located in the inner cavity of the proximal balloon.
4. The balloon catheter with occlusion function of claim 1, wherein the distal end of the inner tube further comprises a tip.
5. The balloon catheter with occlusion function of claim 1, wherein the outer tube and the middle tube are connected by welding or bonding at the RX port.
6. The drug balloon catheter with the occlusion function of claim 1, wherein the outer tube, the middle tube and the infusion tube are connected at the self-infusion port by welding or bonding.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910964307.6A CN110548211B (en) | 2019-10-11 | 2019-10-11 | Medicine balloon catheter with plugging function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910964307.6A CN110548211B (en) | 2019-10-11 | 2019-10-11 | Medicine balloon catheter with plugging function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110548211A CN110548211A (en) | 2019-12-10 |
| CN110548211B true CN110548211B (en) | 2021-08-17 |
Family
ID=68742732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910964307.6A Active CN110548211B (en) | 2019-10-11 | 2019-10-11 | Medicine balloon catheter with plugging function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110548211B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111228639A (en) * | 2020-03-11 | 2020-06-05 | 河南科技大学 | A expansion treatment device for lumen passageway excision postoperative |
| CN111408019A (en) * | 2020-04-29 | 2020-07-14 | 童妍(上海)医疗器械有限公司 | Drug release balloon catheter and drug release method thereof |
| CN115177321B (en) * | 2022-06-14 | 2023-06-20 | 上海腾复医疗科技有限公司 | Multifunctional thrombus removing device |
| CN115463316B (en) * | 2022-08-18 | 2023-09-26 | 广东博迈医疗科技股份有限公司 | Medicine-carrying balloon catheter |
| CN115463320A (en) * | 2022-09-27 | 2022-12-13 | 广东博迈医疗科技股份有限公司 | Medicine applying balloon catheter |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020032405A1 (en) * | 1998-10-15 | 2002-03-14 | Sweezer William P. | Arterial perfusion cannula and method for providing cardiopulmonary bypass |
| CN1158052C (en) * | 2000-02-28 | 2004-07-21 | 鲍平 | Double saccule rack device for non-exchanging subcutaneous puncture coronary artery expansion forming operation |
| CN102125721A (en) * | 2011-03-10 | 2011-07-20 | 微创医疗器械(上海)有限公司 | Novel interventional medical device |
| CN102380156A (en) * | 2011-08-25 | 2012-03-21 | 微创医疗器械(上海)有限公司 | Sectional type balloon expanding catheter |
| CN206325106U (en) * | 2016-10-20 | 2017-07-14 | 深圳市业聚实业有限公司 | Medicinal balloon catheter |
| CN106725696B (en) * | 2017-02-13 | 2019-07-19 | 中国医科大学附属盛京医院 | It is a kind of for blocking the dual balloon catheter of common iliac blood flow |
| CN208160821U (en) * | 2017-05-16 | 2018-11-30 | 恒壹（北京）医疗科技有限公司 | A kind of three sacculus dilating catheter of three chamber |
-
2019
- 2019-10-11 CN CN201910964307.6A patent/CN110548211B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110548211A (en) | 2019-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110548211B (en) | Medicine balloon catheter with plugging function | |
| CN211584835U (en) | Medicine balloon catheter | |
| CN110548212B (en) | Double-balloon catheter with self-perfusion function | |
| EP1996088B1 (en) | Minimally invasive intravascular treatment device | |
| US6159139A (en) | Radiation delivery catheter with a spring wire centering mechanism | |
| US5306250A (en) | Method and apparatus for intravascular drug delivery | |
| CN219440371U (en) | Double-drug administration saccule | |
| JP6068673B2 (en) | Balloon system for the treatment of sinusitis or allergic rhinitis | |
| US20080077165A1 (en) | Minimally Invasive Intravascular Treatment Device | |
| US20080077164A1 (en) | Minimally Invasive Intravascular Treatment Device | |
| JP2004538036A (en) | Drug delivery catheter with high compliant balloon with injection hole | |
| WO2008112464A1 (en) | Agent delivery perfusion catheter | |
| CN109414571B (en) | Medicine elution sacculus | |
| CN104857615A (en) | Novel dual-layer drug balloon catheter | |
| WO2019024726A1 (en) | Balloon catheter with drug coating | |
| CN112370638A (en) | Medicine balloon | |
| US20240115840A1 (en) | Method And Apparatus For Minimizing Excess Drug Delivery | |
| JP2018068724A (en) | Balloon catheter | |
| US20230381468A1 (en) | Inflatable balloon over catheter with bypass passageway | |
| CN211584834U (en) | Double-balloon catheter | |
| CN216653092U (en) | Balloon catheter system | |
| CN218923532U (en) | Medicine-applying saccule catheter | |
| CN219721655U (en) | Lung vessel targeted therapy drug-carrying conveying system | |
| CN115463321B (en) | Administration balloon catheter and administration balloon catheter device | |
| CN216571148U (en) | Bifurcated medicine balloon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Lingsheng Inventor after: Tan Maocai Inventor after: Liu Jiyong Inventor after: Hu Qing Inventor before: Wang Ling Inventor before: Tan Maocai Inventor before: Liu Jiyong Inventor before: Hu Qing |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |